A Study to Evaluate the Frequency of Double Maintenance with Pemetrexed Plus Bevacizumab Discontinuation for Adverse Event and to Describe Main Toxicities Occurring During Double Maintenance in Patients with Non Small Cell Lung Cancer (NSCLC)

Trial Profile

A Study to Evaluate the Frequency of Double Maintenance with Pemetrexed Plus Bevacizumab Discontinuation for Adverse Event and to Describe Main Toxicities Occurring During Double Maintenance in Patients with Non Small Cell Lung Cancer (NSCLC)

Active, no longer recruiting
Phase of Trial: Phase IV

Latest Information Update: 18 Dec 2015

At a glance

  • Drugs Bevacizumab (Primary) ; Pemetrexed (Primary)
  • Indications Non-small cell lung cancer
  • Focus Adverse reactions
  • Most Recent Events

    • 18 Dec 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top